Methotrexat Sandoz (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the regeneration of tetrahydrofolate needed for purine and thymidylate synthesis. This limits DNA, RNA and protein production, especially in fast‑growing cells such as cancerous lymphocytes, synovial fibroblasts, and keratinocytes, leading to reduced proliferation and inflammation.

The dose of Methotrexat Sandoz is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and treatment response. No universal dosing regimen is provided here; the prescriber sets the appropriate amount and schedule.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methotrexat Sandoz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and any required import documentation.

Methotrexat Sandoz shares the core mechanism of dihydrofolate reductase inhibition with other antimetabolites such as pemetrexed, but methotrexate has a broader range of approved indications, including autoimmune diseases. Its pharmacokinetic profile allows multiple routes of administration (IM, IV, intrathecal), whereas some alternatives are limited to oral or specific intravenous formulations.

Methotrexat Sandoz should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the product. If a temporary temperature excursion occurs, follow the manufacturer’s guidance before use.

The product is supplied as a sterile injectable solution and may be given by intramuscular, intravenous, or intrathecal injection, depending on the clinical indication and prescribing information. Administration is performed by qualified healthcare professionals under aseptic conditions, with dosing intervals determined by the treating physician.

Serious adverse events include bone marrow suppression leading to pancytopenia, severe hepatotoxicity that can progress to fibrosis or cirrhosis, and pulmonary toxicity such as interstitial pneumonitis. These risks require regular laboratory monitoring and prompt medical attention if symptoms such as unexplained fever, shortness of breath, or jaundice develop.

Methotrexat Sandoz is contraindicated in patients with known hypersensitivity to methotrexate or any excipients, in pregnant women, and in individuals with severe renal or hepatic impairment where drug clearance is compromised. Caution is also advised for patients with active infections, immunodeficiency, or existing pulmonary disease.